Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid by Matsumoto, Yohsuke et al.
Chemistry
Biochemistry fields
Okayama University Year 2008
Inhibition of tumor-stromal interaction
through HGF/Met signaling by valproic
acid
Yohsuke Matsumoto∗ Takahiro Motoki† Satoshi Kubota‡
Masaharu Takigawa∗∗ Hirohito Tsubouchi†† Eiichi Gohda‡‡
∗Department of Immunochemistry, Okayama University, Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences
†Department of Immunochemistry, Okayama University, Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences
‡Department of Biochemistry and Molecular Dentistry, Okayama University, Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences
∗∗Department of Biochemistry and Molecular Dentistry, Okayama University, Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences
††Digestive Disease and Life-style Related Disease, Health Research Human and Environ-
mental Sciences, Kagoshima University, Graduate School of Medicine and Dental Sciences
‡‡Department of Immunochemistry, Okayama University, Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, gohda@pheasant.pharm.okayama-u.ac.jp
This paper is posted at eScholarship@OUDIR : Okayama University Digital Information
Repository.
http://escholarship.lib.okayama-u.ac.jp/biochemistry/10
Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid 
 
Yohsuke Matsumoto a, Takahiro Motoki a, Satoshi Kubota b, Masaharu Takigawa b,  
Hirohito Tsubouchi c, Eiichi Gohda a,* 
 
a Department of Immunochemistry, Okayama University Graduate School of Medicine, Dentistry 
and Pharmaceutical Sciences, Tsushima-naka,  
Okayama 700-8530, Japan 
b Derpartment of Biochemistry and Molecular Dentistry, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho, Okayama 700-8525, Japan 
c Digestive Disease and Life-style Related Disease, Health Research Human and Environmental 
Sciences, Kagoshima University Graduate School of Medicine and Dental Sciences,  




Eiichi Gohda, Department of Immunochemistry, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka, Okayama 700-8530, Japan 
Tel.: +81-86-251-7960; fax: +81-86-251-7926. 












Hepatocyte growth factor (HGF), which is produced by surrounding stromal cells, including 
fibroblasts and endothelial cells, has been shown to be a significant factor responsible for cancer 
cell invasion mediated by tumor-stromal interactions. We found in this study that the anti-tumor 
agent valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, strongly inhibited 
tumor-stromal interaction. VPA inhibited HGF production in fibroblasts induced by epidermal 
growth factor (EGF), platelet-derived growth factor, basic fibroblast growth factor, phorbol 
12-myristate 13-acetate (PMA) and prostaglandin E2 without any appreciable cytotoxic effect. 
Other HDAC inhibitors, including butyric acid and trichostatin A (TSA), showed similar 
inhibitory effects on HGF production stimulated by various inducers. Up-regulations of HGF 
gene expression induced by PMA and EGF were also suppressed by VPA and TSA. Furthermore, 
VPA significantly inhibited HGF-induced invasion of HepG2 hepatocellular carcinoma cells. 
VPA, however, did not affect the increases in phosphorylation of MAPK and Akt in HGF-treated 
HepG2 cells. These results demonstrated that VPA inhibited two critical processes of 
tumor-stromal interaction, induction of fibroblastic HGF production and HGF-induced invasion 
of HepG2 cells, and suggest that those activities serve for other anti-tumor mechanisms of VPA 
besides causing proliferation arrest, differentiation, and/or apoptosis of tumor cells. 
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Hepatocyte growth factor (HGF), also known as scatter factor, was originally discovered as a 
mitogenic factor of rat hepatocytes in primary culture [1-5]. HGF is now recognized as a 
pleiotropic factor that functions as a mitogen, motogen, morphogen and anti-apoptotic factor 
acting on various types of cells [6,7]. Based on these actions, HGF has been shown to play critical 
roles in developmental and regenerative events of the liver and other tissues [8-11]. In addition to 
regulation of normal cell functions, many studies have shown that HGF is involved in malignant 
cell transformation and growth, invasion and metastasis in tumor cells [12,13]. HGF is mainly 
produced by surrounding stromal cells such as fibroblasts and endothelial cells and stimulates 
growth, metastasis, and/or invasiveness of cancer cells expressing the HGF receptor Met in a 
paracrine manner [14]. Thus, the HGF and Met pathway is one of the most commonly cited 
soluble factor signaling pathways in the tumor-stromal interaction [14]. Clinical studies on 
hepatocellular carcinoma (HCC) have also suggested the involvement of interaction of HGF and 
c-Met in human tumor invasion and metastasis. High levels of serum HGF in patients with HCC 
are associated with tumor metastasis [15]. Therefore, inhibition of fibroblastic HGF production 
and HGF-induced aggressive behavior of tumor cells is expected to suppress proliferation, 
metastasis, and invasiveness of malignant tumor cells, including HCC cells. 
Acetylation and deacetylation of nucleosomal core histones play an important role in the 
modulation of chromatin structure and the regulation of gene expression. The disruption of 
balance between histone acetyltransferases and histone deacetylases (HDACs) has been suggested 
to be associated with cancer development. HDAC activity is increased in cancer cells and has 
been linked to carcinogenesis [16]. Indeed, it has recently been shown that global hypo-acetylation 
of histone H4 is a common feature of human tumor cells [17]. Valproic acid (VPA), an effective 
anticonvulsant in the treatment of epilepsy, as well as butyric acid (BA) inhibits the activity of 
zinc-dependent class I and class II HDACs [18]. HDAC inhibitors induce proliferation arrest, 
differentiation, and/or apoptosis of tumor cells but not of normal cells [17]. Based on these 
activities, HDAC inhibitors have exhibited anti-tumor effects in clinical trials [17,19]. However, 
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the exact mechanisms by which HDAC inhibitors exert an anti-tumor effect and modulate gene 
expression are not completely understood and remain a subject of intense investigation. 
In the present study, we investigated whether VPA affects the HGF and Met pathway in the 
tumor-stromal interaction and we found that VPA potently inhibited two processes of the 
interaction, induction of fibroblastic HGF production and HGF-induced invasion of HepG2 HCC 
cells. Our results suggest that VPA exerts anti-tumor effects at least partly through the inhibition of 
tumor-stromal interaction which may constitute a new class of targets for chemoprevention of 
tumor invasion. 
  
Materials and methods 
 
Cell culture.  Human dermal fibroblasts derived from 200 individual neonatal donors (Cell 
Systems, Kirkland, WA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml 
streptomycin at 37ºC in a humidified atmosphere of 5% CO2 and 95% air as described previously 
[20]. HepG2 cells were obtained from Tohoku University (Sendai, Japan) and cultured in RPMI 
1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 
37ºC in a humidified atmosphere of 5% CO2 and 95% air. 
Determination of HGF production.  The medium of confluent fibroblasts cultured in 96-well 
plates (Nunc, Roskilde, Denmark) was replaced with the fresh medium described in the previous 
section or that containing HDAC inhibitors, and the cells were preincubated for 1 h. HGF inducers 
were then added, and the conditioned medium was collected after being incubated for various 
periods. The sandwich ELISA for human HGF was performed at room temperature as described 
previously [21], with slight modification [22].  
MTT assay.  Confluent fibroblasts were incubated with HDAC inhibitors and HGF inducers 
as described in the previous section. HepG2 cells (5 × 104 cells/0.2 ml/well) seeded in 96-well 
plates (Nunc) were preincubated for 1 h with or without VPA and incubated for 24 h with or 
without HGF in the presence or absence of VPA. The medium was then replaced with 100 µl of 
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the same fresh medium, and the cultures were incubated for 1 h. 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was performed 
as described previously [23].  
Northern blot analysis.  The medium of confluent fibroblasts grown in 90-mm dishes (Nunc) 
was replaced with the same fresh medium, and the cells were incubated for about 15 h. VPA or 
trichostatin A (TSA) was added without a medium change, and the cells were preincubated for 1 h. 
The HGF inducer was then added. After being incubated for 15 or 40 h, total RNA was isolated 
from the cells using RNA Bee (TEL-TEST, Friendswoods, TX). Northern blotting was performed 
as described previously [20].  
Real-time PCR analysis.  The medium of confluent fibroblasts cultured in 6-well plates 
(Nunc) was replaced with the same fresh medium, and the cells were incubated for 24 h. After 
treatment with or without cycloheximide for 1 h, the cells were incubated for 1 h with or without 
VPA and then for an additional 8 h with or without phorbol 12-myristate 13-acetate (PMA). Total 
cellular RNA was isolated as described above. After treatment with DNase, first-strand cDNA 
synthesis from 0.5 μg RNA was performed using reverse transcriptase with random and oligo-dT 
primers. Real-time PCR was performed with a LightCycler (Roche, Indianapolis, IN) using 
SYBR® Green Realtime PCR Master Mix (Toyobo Co., Osaka, Japan) according to the 
manufacturer’s protocol. The nucleotide sequences of primers for HGF were as follows: forward, 
5’-CAATAGCATGTCAAGTGGAG-3’; reverse, 5’-CTGTGTTCGTGTGGTATCAT-3’ 
(amplicon size: 180 bp). The nucleotide sequences of primers for 28S rRNA used as an internal 
control were: forward, 5’-GTTCACCCACTAATAGGGAACG-3’; reverse, 
5’-GGATTCTGACTTAGAGGCGTTC-3’ (amplicon size: 213 bp). The PCR conditions were as 
follows: HGF, 1 cycle of 95ºC for 30 s followed by 60 cycles of 95ºC for 5 s, 57ºC for 0 s and 
72ºC for 25 s; 28S rRNA, 1 cycle of 95ºC for 30 s followed by 55 cycles of 95ºC for 5 s, 60ºC for 
5 s and 72 ºC for 15 s. Relative cDNA copy numbers were computed on the basis of data with a 
serial dilution of a representative sample for each target gene.  
Western blot analysis.  The medium of subconfluent HepG2 cells grown in 24-well plates 
(Nunc) was replaced with the same fresh medium, and the cells were incubated for about 15 h. 
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VPA was added without a medium change, and the cells were preincubated for 1 h. Then, HGF 
was added. After being incubated for an appropriate period, the cells were harvested, and Western 
blotting was performed as described previously [24]. In some experiments, cytosolic and nuclear 
extracts of the cells in 6-well plates (Nunc) were prepared according to the manufacturer’s 
instructions (Active Motif, Carlsbad, CA).  
Cell invasion assay.  The in vitro invasion activities were examined as reported previously 
[25]. Polycarbonate membranes with 8-µm pores of Transwell® inserts (Corning, New York), 
upper culture chambers, were coated with 50 µl of growth factor-reduced MatrigelTM (BD 
Biosciences, San Jose, CA) in cold RPMI 1640 medium (0.25 mg/ml) and dried overnight. 
HepG2 cells suspended in RPMI 1640 medium supplemented with 2% FBS were seeded onto the 
upper culture chambers at a density of 1.5 × 105 cells/cm2 (0.2 ml/well), whereas the lower culture 
chambers of 24-well plates were each filled with 0.8 ml of serum-free RPMI 1640 medium 
containing HGF, VPA or the combination of HGF and VPA. After the incubation for 24 h, the cells 
on the upper surface of the membrane were wiped off with a cotton swab. The cells that had 
invaded the lower surface of membranes were fixed for 10 min with methanol, stained with 
Giemsa solution overnight, and counted under a microscope.   
Statistical analysis.  All results were expressed as means and SEM of several independent 
experiments. The data were analyzed by Dunnett’s t-test, Dunnett’s T3, Tukey’s test or Student’s 




Inhibition by valproic acid and other HDAC inhibitors of HGF induction in human dermal 
fibroblasts 
 
HGF expression has been demonstrated to be up-regulated in stromal cells by tumor 
cell-secreted soluble growth factors, including epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF) and basic fibroblast growth factor (bFGF) [26]. Therefore human dermal 
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fibroblasts were incubated for 72 h with VPA in the presence and absence of suboptimal doses of 
those growth factors. HGF secreted from the cells was then determined by an HGF ELISA. The 
effect of VPA on basal HGF production could hardly be determined because of the small amount 
of HGF produced (data not shown). VPA significantly inhibited EGF-, PDGF- and bFGF-induced 
HGF production with IC50 values of 0.15, 0.19 and 0.17 mM, respectively (Table 1). HGF 
production stimulated by other inducers, PMA, 8-bromo-cAMP and prostaglandin E2 (PGE2), was 
also inhibited by VPA with IC50 values of 0.86, 0.48 and 0.12 mM, respectively (Table 1). The 
number of viable cells in the cultures treated with or not treated with PMA and 8-bromo-cAMP 
was not affected by any concentration of VPA as determined by the MTT method (Fig. 1A and 
1B). On the other hand, VPA inhibited the EGF-induced increase in number of viable cells with 
IC50 of 0.42 mM and up to the level in control cultures at 2 mM (Fig. 1C), whereas cell viability, 
determined by the Trypan Blue-exclusion test, in the cultures treated or not treated with EGF was 
not decreased by VPA (data not shown).  
Next we examined whether other HDAC inhibitors modulate HGF induction in human dermal 
fibroblasts. While BA as well as VPA inhibits class I and class IIa members of the HDAC family, 
TSA inhibits broad-spectrum HDACs [18]. Both BA (2 mM) and TSA (1 μM) also significantly 
inhibited HGF production induced by EGF, PMA, 8-bromo-cAMP and PGE2 (data not shown). 
EGF- and PMA-induced HGF production is accompanied by up-regulation of HGF gene 
expression [26,27]. Effects of VPA and TSA on HGF gene expression up-regulated by PMA or 
EGF are shown in Fig. 2A and 2B. VPA significantly inhibited PMA- and EGF-induced HGF 
mRNA expression by 32% and 81%, respectively. TSA inhibited PMA- and EGF-induced HGF 
mRNA expression by 90% and 61%, respectively. 
 
Inhibition of HGF gene up-regulation by VPA is not blocked by cycloheximide treatment.  
 
HDAC inhibitors generally activate expression of many genes, but the expression of some 
genes, including estrogen receptor α, is down-regulated by histone acetylation induced by HDAC 
inhibitors [28]. Since the down-regulation in most cases is prevented by concomitant treatment 
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with cycloheximide, reduction of gene expression by HDAC inhibitors is presumably dependent 
on the synthesis of transcriptional repressors [28]. Thus, we tested whether VPA-caused repression 
of HGF gene up-regulation induced by PMA is such a case. As shown in Fig. 2C, treatment with 
cycloheximide did not prevent VPA-caused reduction of HGF gene up-regulation.  
 
Inhibition of HGF-induced invasion of HepG2 cells by valproic acid 
 
Tumor-stromal interaction through HGF/c-Met signaling plays an important role in growth, 
invasion, and metastasis of tumor cells. It has been shown that HGF stimulates the invasiveness of 
the human hepatoblastoma cell line HepG2 in a Matrigel cell invasion assay [29,30]. To 
investigate whether VPA affects the cell invasion induced by HGF, HepG2 cells were incubated 
with HGF, VPA or the combination of HGF and VPA for 24 h. The number of cells that invaded 
the filters coated with Matrigel basement membrane matrix were then counted. HGF strongly 
induced the invasion of HepG2 cells, as reported previously [29,30] (Fig. 3A and 3B). Importantly 
VPA significantly suppressed HGF-induced invasion of HepG2 cells (Fig. 3A and 3B), whereas 
the number of viable cells, determined by the MTT assay, in the cultures treated with HGF was 
not decreased by VPA (Fig. 3C). BA (2 mM) and TSA (1 μM) also significantly inhibited 
HGF-induced invasion of HepG2 cells (data not shown). 
It has been suggested that HGF induces cell invasion of HepG2 cells via the ERK pathway 
and phosphatidylinositol 3-kinase (PI3K)-Akt pathway [30,31]. VPA (2 mM), however, did not 
show any significant effect on phosphorylation of ERK and Akt or nuclear translocation of 





Enhancement of cancer cell invasion by stromal fibroblasts has been demonstrated in a variety 
of cancers, including breast, gallbladder, esophageal and prostate cancers [32]. HGF, which is 
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mainly secreted by surrounding stromal cells, including fibroblasts and endothelial cells, has been 
shown to be a significant factor responsible for cancer cell invasion mediated by tumor-stromal 
interactions [14]. Elevated levels of tumor and plasma HGF have been observed in a number of 
cancers such as lung, breast, prostate, and hepatocellular cancers [33]. We demonstrared in this 
study that VPA and other HDAC inhibitors blocked tumor-stromal interactions at two steps: 
inhibition of HGF induction in human dermal fibroblasts and suppression of HGF-induced HepG2 
cell invasion. Thus, HDAC inhibitors have other antitumor mechanisms besides causing 
proliferation arrest, differentiation, and/or apoptosis of tumor cells. 
HGF expression has been demonstrated to become up-regulated in stromal cells by tumor 
cell-secreted soluble cytokines and growth factors, including IL-1α, IL-1β, EGF, PDGF, and 
bFGF [26,27]. PGE2, which is implicated in the proliferation and invasiveness of tumor cells [30], 
also induces HGF production in fibroblasts [20]. Induction of HGF by EGF, other growth factors 
and PGE2 was more sensitive to VPA than was HGF induction by other inducers, the IC50 being 
approximately 0.15 mM. This concentration is clinically achieved in plasma of patients treated 
with VPA for epilepsy, e.g., a mean trough plasma level of 0.44 mM after 3-month treatment with 
an average daily dose of 720 mg [34]. The values in the MTT assay of cultures of human dermal 
fibroblasts and HepG2 cancer cells were not decreased by treatment with VPA except for those in 
EGF-stimulated human dermal fibroblasts. In accordance with the known antiproliferative activity 
of the short-chain fatty acid, VPA decreased the values in the MTT assay induced by EGF up to 
those of control cultures not treated with EGF. In addition, VPA did not decrease cell viability, 
determined by the Trypan Blue-exclusion test, in cultures treated or not treated with EGF. These 
findings collectively indicate that VPA is not cytotoxic to the cells. 
Histone acetylation causes alteration of nucleosomal conformation and thus increases the 
accessibility of transcriptional regulatory proteins to chromatin templates and subsequent 
transcription [35]. These changes are thought to be one mechanism by which HDAC inhibitors 
generally activate expression of many genes. Nevertheless, the expression of some genes, 
including estrogen receptor α gene, the oncogene MYC and tumor suppressor gene p53, is 
down-regulated by histone acetylation induced by HDAC inhibitors [28]. Since VPA- and 
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TSA-caused reduction in expression of most of those genes is blocked by concomitant treatment 
with cycloheximide, down-regulation of those genes by HDAC inhibitors is presumably 
dependent on the synthesis of transcriptional repressors [28]. Inhibition of up-regulated HGF gene 
expression by VPA, however, was not prevented by cycloheximide and was thus not such a case. 
VPA potently inhibited HepG2 cell invasion induced by HGF without suppressing cell 
proliferation. Cell invasion is a major event involved in the complex multistep process of tumor 
metastasis. Invasion of tumor cells requires destruction of basement membranes, proteolysis of 
extracellular matrix (ECM), pseudopodial extension, and cell migration [36]. After modifying the 
ECM barrier, tumor cells migrate through the barrier and proliferate at a secondary site. HGF is 
one of the potent motility factors and contributes to metastasis by stimulation of motility [12]. 
Activation of PI3K-Akt and ERK pathways has been suggested to be critical for cell motility 
stimulated by HGF [30,31,37], but phosphorylation of neither Akt nor ERK in HepG2 cells 
stimulated with HGF was reduced by treatment with VPA. Although its mechanism remains to be 
investigated, inhibition of tumor cell invasion by HDAC inhibitors may constitute a new class of 
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Figure 1.  VPA has no cytotoxic effects on fibroblasts treated with or without PMA and 
8-bromo-cAMP and inhibits EGF-induced cell proliferation. Confluent cells were preincubated for 
1 h with the indicated concentrations of VPA and then incubated for 24 h with or without 3 nM 
PMA and for 72 h with or without 0.3 mM 8-bromo-cAMP or 3 ng/ml of EGF in the presence or 
absence of VPA. The number of viable cells was measured by the MTT method. The data are 
means ± SEM of three independent experiments. *P < 0.05, ***P < 0.001, as compared with the 
values of medium alone or respective inducer alone. 
 
Figure 2.  VPA- and TSA-caused inhibition of HGF gene expression up-regulated by PMA or 
EGF and effects of cycloheximide on VPA-caused inhibition. (A, B) Confluent fibroblasts were 
preincubated for 1 h with or without 2 mM VPA or 1 µM TSA and then incubated for 15 h with or 
without 3 nM PMA or for 40 h with or without 3 ng/ml of EGF in the presence or absence of VPA 
or TSA. The signal intensity of the 6.4-kb HGF mRNA band in the autoradiograms was 
normalized to the fluorescence intensity of the 28S rRNA band, and results are expressed as 
relative levels to the value of untreated cells. The data are means of three independent experiments. 
Bars indicate SEM. **P < 0.01, ***P < 0.001, as compared with the values of medium alone or 
respective inducer alone. (C) Confluent fibroblasts were preincubated for 1 h with or without 1 
μg/ml of cycloheximide (CHX) and then for 1 h with or without 2 mM VPA followed by 
incubation for an additional 8 h with or without 3 nM PMA. The expression levels of HGF mRNA 
and 28S rRNA were measured by real-time PCR. Results are expressed as relative levels to the 
value of untreated cells after being normalized to the 28S rRNA levels. The data are means of 
three independent experiments. Bars indicate SEM. *P < 0.05, **P < 0.01, as compared with the 
values of the respective PMA alone. 
 
Figure 3.  Inhibition of HGF-induced invasion of HepG2 cells by VPA. (A, B) HepG2 cells, 
seeded onto the upper chamber consisting of filters coated with MatrigelTM, were preincubated for 
 15
 16
1 h with or without of 2 mM VPA added to the lower chamber and then incubated for 24 h with or 
without 10 ng/ml of HGF added to the lower chamber. Cells that invaded the filter were visualized 
and counted microscopically at × 200 magnifications. Scale bar=100 μm. (C) HepG2 cells seeded 
in 96-well plates were preincubated for 1 h with or without 2 mM VPA and incubated for 24 h 
with or without 10 ng/ml of HGF in the presence or absence of VPA. The number of viable cells 
was then measured by the MTT method. The data are means of four (invasion) or three (MTT) 
independent experiments. Bars indicate SEM. *P < 0.05, as compared with the values of medium 
alone or HGF alone. NS, not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
